Abdel-Rahman, O. (2016). Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: A network meta-analysis. Therapeutic Advances in Medical Oncology, 8, 396–406.

DOI Link

Purpose

STUDY PURPOSE: To conduct a meta-analysis comparing the effectiveness of NK₁ inhibitors in preventing chemotherapy-induced nausea and vomiting (CINV) attributed to highly emetogenic chemotherapy (HEC)

TYPE OF STUDY: Meta-analysis and systematic review

Search Strategy

DATABASES USED: MEDLINE, Cochrane Library, Google Scholar, meeting abstracts

INCLUSION CRITERIA: Clinical studies evaluating antiemetic regimens preventing CINV related to HEC in adults; efficacy measures were reported.

EXCLUSION CRITERIA: Non-English language

Literature Evaluated

TOTAL REFERENCES RETRIEVED: 699

EVALUATION METHOD AND COMMENTS ON LITERATURE USED: PRISMA guidelines were used for study selection; data were analyzed using a Bayesian meta-analysis approach (efficacy assessed using ranks, odd ratios estimated); study quality evaluated using Jadad quality assessment method

Sample Characteristics

FINAL NUMBER STUDIES INCLUDED = 19
TOTAL PATIENTS INCLUDED IN REVIEW = 6,788
SAMPLE RANGE ACROSS STUDIES: 16–359
KEY SAMPLE CHARACTERISTICS: Receiving highly emetogenic chemotherapy (HEC)

Phase of Care and Clinical Applications

PHASE OF CARE: Active antitumor treatment

Results

Antiemetic regimens including an NK₁ inhibitor (aprepitant, fosaprepitant, rolapitant, casopitant, netupitant) prevent CINV attributed to HEC significantly more than antiemetic regimens that do not include it.

Conclusions

Antiemetic regimens containing an NK₁ inhibitor prevent CINV attributed to HEC better than regimens that do not contain it.

Nursing Implications

Antiemetic regimens should include an NK₁ inhibitor to maximally prevent CINV.

Legacy ID

6385